These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 24928797)

  • 1. Novel therapeutic approaches in multiple system atrophy.
    Palma JA; Kaufmann H
    Clin Auton Res; 2015 Feb; 25(1):37-45. PubMed ID: 24928797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.
    Ubhi K; Rockenstein E; Mante M; Patrick C; Adame A; Thukral M; Shults C; Masliah E
    Neuroreport; 2008 Aug; 19(13):1271-6. PubMed ID: 18695506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy.
    Ettle B; Kerman BE; Valera E; Gillmann C; Schlachetzki JC; Reiprich S; Büttner C; Ekici AB; Reis A; Wegner M; Bäuerle T; Riemenschneider MJ; Masliah E; Gage FH; Winkler J
    Acta Neuropathol; 2016 Jul; 132(1):59-75. PubMed ID: 27059609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Models of multiple system atrophy.
    Fellner L; Wenning GK; Stefanova N
    Curr Top Behav Neurosci; 2015; 22():369-93. PubMed ID: 24338664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1.
    Jellinger KA
    J Alzheimers Dis; 2018; 62(3):1141-1179. PubMed ID: 28984582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease.
    Marmion DJ; Rutkowski AA; Chatterjee D; Hiller BM; Werner MH; Bezard E; Kirik D; McCown T; Gray SJ; Kordower JH
    Neurobiol Dis; 2021 Jan; 148():105184. PubMed ID: 33221532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy.
    Heras-Garvin A; Weckbecker D; Ryazanov S; Leonov A; Griesinger C; Giese A; Wenning GK; Stefanova N
    Mov Disord; 2019 Feb; 34(2):255-263. PubMed ID: 30452793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapidly progressive multiple system atrophy-cerebellar variant model presenting marked glial reactions with inflammation and spreading of α-synuclein oligomers and phosphorylated α-synuclein aggregates.
    Yamaguchi H; Nishimura Y; Matsuse D; Sekiya H; Masaki K; Tanaka T; Saiga T; Harada M; Kira YI; Dickson DW; Fujishima K; Matsuo E; Tanaka KF; Yamasaki R; Isobe N; Kira JI
    Brain Behav Immun; 2024 Oct; 121():122-141. PubMed ID: 38986725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligodendroglial α-synucleinopathy-driven neuroinflammation in multiple system atrophy.
    Hoffmann A; Ettle B; Battis K; Reiprich S; Schlachetzki JCM; Masliah E; Wegner M; Kuhlmann T; Riemenschneider MJ; Winkler J
    Brain Pathol; 2019 May; 29(3):380-396. PubMed ID: 30444295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy.
    Herrera-Vaquero M; Bouquio D; Kallab M; Biggs K; Nair G; Ochoa J; Heras-Garvin A; Heid C; Hadrovic I; Poewe W; Wenning GK; Klärner FG; Schrader T; Bitan G; Stefanova N
    Biochim Biophys Acta Mol Basis Dis; 2019 Nov; 1865(11):165513. PubMed ID: 31319154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure.
    Stemberger S; Poewe W; Wenning GK; Stefanova N
    Exp Neurol; 2010 Aug; 224(2):459-64. PubMed ID: 20493840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathology of multiple system atrophy: new thoughts about pathogenesis.
    Jellinger KA
    Mov Disord; 2014 Dec; 29(14):1720-41. PubMed ID: 25297524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy.
    Stefanova N; Reindl M; Neumann M; Kahle PJ; Poewe W; Wenning GK
    Mov Disord; 2007 Nov; 22(15):2196-203. PubMed ID: 17853477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy.
    Koga S; Dickson DW
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):175-184. PubMed ID: 28860330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions.
    Kaji S; Maki T; Ishimoto T; Yamakado H; Takahashi R
    Transl Neurodegener; 2020; 9():7. PubMed ID: 32095235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications.
    Kaindlstorfer C; Sommer P; Georgievska B; Mather RJ; Kugler AR; Poewe W; Wenning GK; Stefanova N
    Neurotox Res; 2015 Oct; 28(3):185-94. PubMed ID: 26194617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity.
    Kuzdas-Wood D; Fellner L; Premstaller M; Borm C; Bloem B; Kirik D; Wenning GK; Stefanova N
    BMC Neurosci; 2015 Dec; 16():86. PubMed ID: 26627686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prodegenerative IκBα expression in oligodendroglial α-synuclein models of multiple system atrophy.
    Kragh CL; Gysbers AM; Rockenstein E; Murphy K; Halliday GM; Masliah E; Jensen PH
    Neurobiol Dis; 2014 Mar; 63():171-83. PubMed ID: 24361600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy.
    Bassil F; Fernagut PO; Bezard E; Pruvost A; Leste-Lasserre T; Hoang QQ; Ringe D; Petsko GA; Meissner WG
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9593-8. PubMed ID: 27482103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models.
    Vidal-Martinez G; Segura-Ulate I; Yang B; Diaz-Pacheco V; Barragan JA; De-Leon Esquivel J; Chaparro SA; Vargas-Medrano J; Perez RG
    Exp Neurol; 2020 Mar; 325():113120. PubMed ID: 31751571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.